Camp4 Therapeutics Corp CAMP
We are a clinical-stage biopharmaceutical company pioneering the discovery and development of a new class of RNA-targeting therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a broad range of genetic diseases. Our lead product candidate, CMP-002, has the potential to be the first disease-modifying therapy for the treatment of synaptic Ras GTPase activating protein 1 ("SYNGAP1")-related disorder, or SYNGAP1, a severe developmental and epileptic encephalopathy ("DEE") characterized by seizures, developmental delays, and cognitive impairments. SYNGAP1 is caused by haploinsufficiency of the SYNGAP1 gene, where mutation of one gene copy results in a reduction in functional SYNGAP protein levels of up to 50%. While we believe that it remains underdiagnosed, we estimate that there are approximately 21,000 individuals living with SYNGAP1 in the United States and the five largest European markets. There are no approved disease-modifying therapies for SYNGAP1.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $3.5M | $652.0K | $350.0K | — |
| R&D | $38.2M | $38.8M | $40.6M | — |
| SG&A | $17.4M | $14.9M | $11.6M | — |
| Total operating expenses | $56.1M | $53.7M | $52.2M | — |
| Operating income | -$52.6M | -$53.1M | -$51.9M | — |
| Pre-tax income | -$80.4M | -$51.8M | -$49.3M | — |
| Income tax | $0 | $0 | $0 | — |
| Net income | -$80.4M | -$51.8M | -$49.3M | — |
| EPS, basic | -2.65 | -11.04 | -124.80 | — |
| EPS, diluted | -2.65 | -11.04 | -124.80 | — |
| Shares, diluted (wtd. avg.) | 30.4M | 4.7M | 394,976 | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | $109.5M | $64.0M | $40.0M | $84.5M |
| Total current assets | $114.1M | $66.4M | $40.0M | — |
| Property, plant and equipment | — | $3.9M | $4.8M | — |
| Total assets | $117.8M | $78.3M | $54.9M | — |
| Accounts payable | $182.0K | $1.2M | $1.0M | — |
| Total current liabilities | $15.5M | $9.6M | $7.8M | — |
| Total liabilities | $70.1M | $15.2M | $16.5M | — |
| Retained earnings | -$292.2M | -$211.8M | -$160.0M | — |
| Total equity | $47.7M | $63.1M | -$123.7M | -$77.5M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating cash flow | -$29.6M | -$45.6M | -$44.2M | — |
| Depreciation and amortisation | $1.6M | $1.7M | $1.7M | — |
| Stock-based compensation | $4.0M | $4.0M | $2.9M | — |
| Capital expenditure | $279.0K | $441.0K | $678.0K | — |
| Investing cash flow | -$243.0K | -$441.0K | -$678.0K | — |
| Financing cash flow | $75.9M | $71.7M | $301.0K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001736730-26-000016.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | — | $350.0K | $652.0K | $3.5M |
| Gross profit | — | — | — | — |
| Net income | — | -$49.3M | -$51.8M | -$80.4M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Regulation FD disclosure Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Regulation FD disclosure Item 7.01
- Results announced Item 2.02
- Officer or director change Item 5.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |